ReviewAdvanced pharmaceutical bulletin2025
The Role of Extracellular Vesicles in Neuropsychiatric Disorders.
Review in Advanced pharmaceutical bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Maternal Extracellular Vesicles During Pregnancy and Autism Risk in Children.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: There are effective treatments available for neuropsychiatric disorders; however, numerous factors such as misdiagnosis, delayed diagnosis, varying types of onsets and progression of disorder, as well as long timeframes between diagnosis and treatment, all serve to limit the ability of these treatments to reduce symptoms. This article discusses the unique theragnostic aspects of extracellular vesicles (EVs) in relation to these clinical considerations. Methods: An extensive review of the literature was conducted to examine recent findings about EVs and their potential role in early diagnosis and targeted treatment of neuropsychiatric disorders, to examine the biological aspects, diagnostic and therapeutic capacity. Results: Pathological states radically change the composition of EVs and their cargo delivery, thereby providing a dynamic disease state. EVs can cross biological barriers, have systemic distribution, provide low immunogenicity and toxicity, and all serve to represent the beginnings of identifying early biomarkers and future methods for delivering therapy needed to administer neuroactive drugs/delivery methods. Conclusion: In summary, EVs have potential as a theragnostic platform for neuropsychiatric diseases. Because they offer passive, non-invasive, and actionable diagnostic insights, EVs can be applied to therapeutically manage neuropsychiatric disorders, which could provide a solution to issues faced in clinical practice, such as late-stage diagnosis and poor treatment compliance. To fully understand the prospect of EVs in neuropsychiatric practice, more translational research and clinical validation are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.